Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherDebates

Rebuttal: Should we avoid β-agonists for moderate and severe chronic obstructive pulmonary disease?

NO

Shawn D. Aaron
Canadian Family Physician September 2007, 53 (9) 1429-1430;
Shawn D. Aaron
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Dr Salpeter argues that monotherapy with β-agonists might be dangerous for patients with asthma. This could be true; however, the question being debated concerns β-agonist use for chronic obstructive pulmonary disease (COPD), not for asthma. Many large clinical trials and properly done metaanalyses1 have confirmed that β-agonists are extremely effective at improving lung function, relieving dyspnea, improving quality of life, and preventing exacerbations among patients with COPD.2,3 Recent large clinical trials have also confirmed that βagonists are safe for patients with COPD.

The 1 meta-analysis that diverges from all of the rest is the meta-analysis done by Dr Salpeter.4 This meta-analysis had serious flaws. Only 4 published trials studying β-agonists were included, even though more than 15 trials were available in the literature. Furthermore, the authors did not attempt to obtain mortality data from many of the pivotal randomized controlled trials published on this subject. The 4 trials included in the meta-analysis contained duplicate publications. Sixty percent of the results of the Salpeter meta-analysis came from the results of only 1 study. The results of this meta-analysis are simply unreliable.

The TORCH (Towards a Revolution in COPD Health) trial, a randomized double-blind placebo-controlled clinical trial, unequivocally showed that 1521 COPD patients treated with the long-acting β-agonist salmeterol for 3 years had a slightly greater (but not statistically significant) chance of survival over 3 years than 1524 patients treated with placebo had (hazard ratio 0.88, 95% confidence interval [CI] 0.73 to 1.06).5 Many more patients were included in the TORCH trial then were included in the entire Salpeter meta-analysis of 4 studies. In addition, patients treated with fluticasone-salmeterol combination products showed a 3-year survival benefit compared with patients given placebo (hazard ratio 0.83, 95% CI 0.68 to 1.00). Patients treated with either salmeterol or fluticasone-salmeterol combinations had improved lung function, improved quality of life, and 15% to 25% fewer exacerbations than those treated with placebo. Therefore long-acting β-agonists and inhaled steroid–long-acting β-agonist combination products appear to improve lung function and quality of life, decrease exacerbations, and also slightly improve survival. They unquestionably do not kill people with COPD!

Footnotes

  • These rebuttals are responses from the authors who were asked to discuss whether β-agonists should be avoided for moderate and severe chronic obstructive pulmonary disease in the Debates section of the August issue (Can Fam Physician 2007;53:1290–3 [Eng], 1294–7 [Fr]).

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Appleton S,
    2. Poole P,
    3. Smith B,
    4. Veale A,
    5. Lasserson T,
    6. Chan M
    . Long-acting beta 2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3:CD001104.
    OpenUrlPubMed
  2. ↵
    1. Stockley RA,
    2. Chopra N,
    3. Rich L
    . Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006;61:122-8.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Rennard SI,
    2. Anderson W,
    3. ZuWallck R,
    4. Broughton J,
    5. Bailey W,
    6. Friedman M,
    7. et al
    . Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087-92.
    OpenUrlPubMed
  4. ↵
    1. Salpeter SR,
    2. Buckley NS,
    3. Salpeter EE
    . Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006;21:1011-9.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Calverley PM,
    2. Anderson JA,
    3. Celli B,
    4. Ferguson GT,
    5. Jenkins C,
    6. Jones PW,
    7. et al
    . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 53 (9)
Canadian Family Physician
Vol. 53, Issue 9
1 Sep 2007
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rebuttal: Should we avoid β-agonists for moderate and severe chronic obstructive pulmonary disease?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rebuttal: Should we avoid β-agonists for moderate and severe chronic obstructive pulmonary disease?
Shawn D. Aaron
Canadian Family Physician Sep 2007, 53 (9) 1429-1430;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Rebuttal: Should we avoid β-agonists for moderate and severe chronic obstructive pulmonary disease?
Shawn D. Aaron
Canadian Family Physician Sep 2007, 53 (9) 1429-1430;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Debates: what good are they?
  • Réfutation: Faut-il éviter les β-agonistes dans les cas de bronchopneumopathies chroniques obstructives modérées et graves?
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Will the new opioid guidelines harm more people than they help?
  • Will the new opioid guidelines harm more people than they help?
  • Should peanut be allowed in schools?
Show more Debates

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2021 by The College of Family Physicians of Canada

Powered by HighWire